Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 23, 2020

Medidata to support trials of Moderna’s Covid-19 vaccine candidate

American technology firm Medidata, a subsidiary of Dassault Systèmes, will support clinical trials of Moderna’s Covid-19 vaccine candidate ‘mRNA-1273’ after the companies entered a partnership.

American technology firm Medidata, a subsidiary of Dassault Systèmes, will support clinical trials of Moderna’s Covid-19 vaccine candidate ‘mRNA-1273’ after the companies entered a partnership.

Medidata’s set of technologies will support in the development of Moderna’s mRNA-1273 clinical trials, which also includes the Phase III trial.

The Phase III trial is expected to enrol 30,000 participants.

With the help of Medidata’s Cloud platform for clinical development, teams from both companies are moving further with the urgency, which has been necessitated as a result of the global pandemic.

Medidata co-founder and co-CEO Tarek Sherif said: “We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society.

“The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Medidata noted that this clinical trial incorporates data captured directly from participants, reducing the need for office visits.

The ‘virtualisation’ of the trial enables participants to use their own devices, relieving the burden of carrying a separate, ‘provisioned’ device.

Moderna chief digital and operational excellence officer Marcello Damiani said: “We are pleased to collaborate with Medidata.

“Medidata’s unified platform is helping us put participants at the center of our efforts to develop a safe and effective vaccine against Covid-19.”

In April this year, Medidata launched an advanced, intuitive platform called myMedidata for patients.

In February, Medidata and Project ALS entered a research partnership in order to develop new therapeutic strategies for the treatment of Amyotrophic lateral sclerosis (ALS).

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU